Related Experiment Videos
Primary central nervous system lymphomas in immunocompetent patients
G Guinto1, I Félix, N Aréchiga
1Department of Neurosurgery, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Mexico City, Mexico. gguinto@prodigy.net.mx
Histology and Histopathology
|May 29, 2004
Summary
Primary Central Nervous System Lymphoma (PCNSL) affects immunocompetent individuals, typically around age 60. Diagnosis relies on stereotactic biopsy, with treatment involving chemotherapy and radiotherapy, though outcomes remain challenging.
Area of Science:
- Neuro-oncology
- Hematology
- Pathology
Background:
- Primary Central Nervous System Lymphoma (PCNSL) is a rare non-Hodgkin's tumor primarily affecting the brain.
- Traditionally associated with immunodeficiency, PCNSL also occurs in immunocompetent patients.
Purpose of the Study:
- To describe the characteristics, diagnosis, and treatment of PCNSL in immunocompetent patients.
- To highlight the clinical and pathological features of this rare brain tumor.
Main Methods:
- Review of clinical and pathological data from immunocompetent patients diagnosed with PCNSL.
- Histological examination including immunohistochemistry and electron microscopy.
- Diagnosis confirmed via stereotactic biopsy.
Main Results:
- PCNSL in immunocompetent patients typically presents in individuals around 60 years old, with a slight female predominance.
- Tumors are often solitary, supratentorial, and characterized by perivascular B-lymphocyte infiltration.
- Coagulative necrosis is less common than in immunodeficiency-related cases.
Conclusions:
- PCNSL in immunocompetent individuals shares histological similarities with systemic lymphomas.
- Current treatment combining chemotherapy and radiotherapy yields high mortality rates.
- Further research into classification and treatment is needed for improved clinical significance.